Supernus Pharmaceuticals Inc SPN-812 Phase III Topline Results Conference Call
Llamada en conferencia Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc Conference call will be held on 06-dic-2018. During the earnings conference call's session Supernus Pharmaceuticals Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Supernus Pharmaceuticals Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. In 2013, we launched Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), our two novel treatments for patients with epilepsy. In addition, we are developing multiple product candidates in psychiatry to address significant unmet medical needs and market opportunities for the treatment of Impulsive Aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). With SPN-810, we are initially developing the product to treat IA in patients who have ADHD. There are currently no approved products indicated for the treatment of IA. We subsequently plan to develop SPN-810 for treatment of IA in other CNS diseases, such as autism, bipolar disorder, schizophrenia, and some forms of dementia.Leer más Llamada en conferencia